All Stories

  1. Coadministered pneumococcal conjugate vaccine decreases immune response to hepatitis A vaccine: a randomized controlled trial
  2. Immune memory persistence is well documented for hepatitis A vaccines
  3. Clinical, serological and epidemiological features of hepatitis A in León, Nicaragua
  4. Immunological and epidemiological long-term effects of hepatitis A vaccination
  5. Hepatitis A vaccination in immunocompromised patients – the need for individualized vaccination strategies and correct methodology
  6. Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases—a prospective multi-centre cohort study
  7. Serologic differential diagnosis of hepatitis A virus (HAV) infected and vaccinated individuals: How long persist antibodies to non-structural HAV proteins?
  8. An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression – A prospective, open-label, multi-center study
  9. Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response
  10. Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR
  11. Changing from whole-cell to acellular pertussis vaccines would trade superior tolerability for inferior protection
  12. Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study
  13. Decreasing Risk of Hepatitis A Infection in León, Nicaragua: Evidence from Cross-Sectional and Longitudinal Seroepidemiology Studies
  14. Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature
  15. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae
  16. Kinetics of maternally acquired anti-hepatitis A antibodies: Prediction of waning based on maternal or cord blood antibody levels
  17. Surveying adverse event rates: lessons from a virosomal hepatitis A vaccine
  18. The phylogeny of yellow fever virus 17D vaccines
  19. Real-life versus package insert: A post-marketing study on adverse-event rates of the virosomal hepatitis A vaccine Epaxal® in healthy travellers
  20. Successful Memory Response following a Booster Dose with a Virosome-Formulated Hepatitis A Vaccine Delayed Up to 11 Years
  21. Immunogenicity and reactogenicity of a combined fully liquid DTPw–HepB–Hib pentavalent vaccine in healthy infants: no clinically relevant impact of a birth dose of hepatitis B vaccine
  22. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine
  23. A fully liquid DTPw-HepB-Hib combination vaccine for booster vaccination of toddlers in El Salvador
  24. Virosomal Hepatitis A Vaccine: Comparing Intradermal and Subcutaneous With Intramuscular Administration
  25. Eleven years of Inflexal® V—a virosomal adjuvanted influenza vaccine
  26. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration
  27. Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptor HAVcr-1 on T cells after hepatitis A re-vaccination in high and low-responder vaccinees
  28. Concomitant Administration of a Virosome-Adjuvanted Hepatitis A Vaccine With Routine Childhood Vaccines at Age Twelve to Fifteen Months: A Randomized Controlled Trial
  29. Immunogenicity and Safety of a Pediatric Dose of a Virosome-Adjuvanted Hepatitis A Vaccine
  30. Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers
  31. Immunogenicity and Safety of a Virosomal Hepatitis A Vaccine (Epaxal ® ) in the Elderly
  32. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria–tetanus–pertussis vaccine (DTP-Hib), in Indonesian infants
  33. Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers’ diarrhoea in a randomised, double-blind, placebo-controlled study
  34. Unique Characteristics of the Intestinal Immune System as an Inductive Site after Antigen Reencounter
  35. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch
  36. Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine
  37. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children
  38. Successful Booster Antibody Response up to 54 Months after Single Primary Vaccination with Virosome-Formulated, Aluminum-Free Hepatitis A Vaccine
  39. Efficacy of Virosome Hepatitis A Vaccine in Young Children in Nicaragua: Randomized Placebo‐Controlled Trial
  40. Virosome influenza vaccine in children
  41. Efficacy of Intranasal Virosomal Influenza Vaccine in the Prevention of Recurrent Acute Otitis Media in Children
  42. Intranasal influenza vaccine: protective efficacy in children and adults
  43. Detection of antibodies to HAV 3C proteinase in experimentally infected chimpanzees and in naturally infected children
  44. Local and systemic immune responses to combined Vibrio cholerae CVD103-HgR and Salmonella typhi Ty21a live oral vaccines after primary immunization and reimmunization
  45. Safety and Immunogenicity of Intranasally Administered Inactivated Trivalent Virosome‐Formulated Influenza Vaccine Containing Escherichia coli Heat‐Labile Toxin as a Mucosal Adjuvant
  46. Immune Response to Rabies Booster Vaccination in Subjects Who Had Postexposure Treatment More Than 5 Years Previously
  47. Compatible Concurrent Administration of Yellow Fever 17D Vaccine with Oral, Live, Attenuated Cholera CVD103‐HgR and Typhoid Ty21a Vaccines
  48. Compatible Concurrent Administration of Yellow Fever 17D Vaccine with Oral, Live, Attenuated Cholera CVD103-HgR and Typhoid Ty21a Vaccines
  49. Asylsuchende und Fl�chtlinge in der haus�rztlichen Praxis: Probleme und Entwicklungsm�glichkeiten
  50. Live oral cholera vaccine
  51. Safety and Immunogenicity of Live Oral Cholera and Typhoid Vaccines Administered Alone or in Combination with Antimalarial Drugs, Oral Polio Vaccine, or Yellow Fever Vaccine
  52. Mumpsepidemiologie ? weltweit
  53. Inactivated virosome hepatitis A vaccine
  54. Neue Bücher
  55. Neue Bücher
  56. SEROLOGICAL DIAGNOSIS OF STAPHYLOCOCCAL BACTERAEMIA
  57. Zur Eliminierung von Masern, Mumps und Röteln in der Schweiz
  58. Neue Bücher
  59. Intranasal interferon (rIFN-αA, Ro 22-8181) for contact prophylaxis against common cold: A randomized, double-blind and placebo-controlled field study
  60. Neue Bücher
  61. TUBERCULIN SENSITIVITY TESTING
  62. DETECTING TUBERCULIN SENSITIVITY
  63. Schutzimpfungen: Stand 1982
  64. REASON FOR VARIABLE RESPONSE TO TUBERCULIN TINE TEST
  65. Berichtigung
  66. Drug treatment of typhoid fever.
  67. Chemotherapy of typhoid fever: A review of literature
  68. CHLORAMPHENICOL-RESISTANT SALMONELLA TYPHI